Adagio Medical Reports Positive vCLAS Results for VT
LOS ANGELES, April 2026 Adagio Medical announced positive pivotal clinical results for its vCLAS® Ventricular Ablation System, highlighting a...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
LOS ANGELES, April 2026 Adagio Medical announced positive pivotal clinical results for its vCLAS® Ventricular Ablation System, highlighting a...
LAGUNA HILLS, Calif., March 19, 2026 Adagio Medical Holdings, Inc. announced successful outcomes from Expanded Access Program (EAP) cases...
